Santa Monica, CA, March 20, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced the Company has formed an Advisory Board to complement the existing Board of Directors and Scientific Advisory Board.
The goal of the newly formed Board is to advise the leadership of BioSig on a range of subjects, including strategy, marketing, government affairs, partnerships, mergers and acquisitions, intellectual property, and capital markets. The Board will be limited to nine members and will consist of thought leaders in business, finance, healthcare and high technology industries.
The first two Advisory Board members are Mr. Kent Bennett Williams, CEO and Principal of Vista Asset Management, LLC and Executive Advisor to Sherpa Technology Group, and Dr. Ramachandra Malya, M.D., a Medical Director and leading nephrologist.
Mr. Williams brings over 30 years of experience in capital markets, strategic investments and business development across the life science, automotive and technology sectors. Most recently, Mr. Williams served as an independent director and adviser to private and public companies such as Sherpa Technology Group, Ener-Core, ViZn Energy Systems, ZAF Energy Systems and ITUS Corporation. He provided strategic counsel at Merrill Lynch & Co. and was appointed Vice Chairman of the American Stock Exchange ITAC Committee. Mr. William’s contributions to BioSig will continue to be in the areas of intellectual property creation and strategy, financing strategy, shareholder development, and manufacturing.
“BioSig team has developed a platform technology with significant business and industrial applications. In my extensive investment career, I have only seen a handful of these come along, and I’m delighted to contribute my expertise to further enhance BioSig business development,” commented Mr. Williams.
Dr. Malya brings to BioSig over 40 years of experience in the medical field. His strong business acumen has allowed Dr. Malya to serve as Founding Board Member of several successful healthcare entities and two Texas savings banks with valuations in excess of one billion dollars. Throughout his career, Dr. Malya raised capital for a number of promising healthcare start-ups and managed an important family office funds with extensive medical relationships. Dr. Malya is a Diplomate of American Board of Internal Medicine and American College of Managed Care Medicine.
“As a physician, I’ve always been drawn to novel clinical research, which aims to enhance patient care. The field of bioelectronic medicine is of special interest to me, and I’m very pleased to collaborate with BioSig and share my knowledge on clinical research and market penetration,” said Dr. Malya.
“We wanted to appoint a proactive Advisory Board, which brings fresh thinking, skills and expertise to enhance our Company’s performance. Kent and Dr. Malya bring impressive career achievements, which will deliver immediate impact in the top priority areas of our business,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.